JIBRAN AHMED: Open Payments
NPI 1992311823 · NEWPORT BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$813 in 30 payments from 9 companies in 2025. Trend: 2023 $79 · 2024 $116 · 2025 $813
Food & beverage: $813
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $171 |
| Alkermes, Inc. | 6 | $124 |
| Janssen Pharmaceuticals, Inc | 4 | $112 |
| Vanda Pharmaceuticals Inc. | 3 | $105 |
| ABBVIE INC. | 5 | $96 |
| Supernus Pharmaceuticals, Inc. | 4 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $64 |
| Janssen Scientific Affairs, LLC | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: REXULTI, SPRAVATO, ARISTADA, HETLIOZ, VRAYLAR, CAPLYTA, Qelbree, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
